CMPS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Compass Pathways PLC (CMPS) is not a strong buy at the moment for a beginner, long-term investor with $50,000-$100,000 available for investment. While the company has promising clinical trial results and analyst ratings remain positive, the financial performance is weak, with significant losses and no revenue growth. Technical indicators are neutral, and there are no strong proprietary trading signals today. Given the lack of immediate catalysts and the high-risk profile, it is advisable to hold off on investing in CMPS at this time.
The MACD histogram is negative (-0.109) but contracting, indicating a weak bearish trend. The RSI is at 39.746, which is neutral, suggesting no clear momentum. Moving averages are converging, showing indecision in price direction. Key support is at $5.069, and resistance is at $6.704. Overall, the technical indicators suggest a neutral trend.
Positive clinical trial results for COMP360 in treatment-resistant depression, with plans for FDA NDA submission.
Hedge funds are significantly increasing their positions, with a 302.54% increase in buying over the last quarter.
Analysts maintain a generally positive outlook, with multiple Buy ratings and price targets ranging from $14 to $22.
Weak financial performance, with significant losses (-$93.88M net income in Q4
and no revenue growth.
Recent Q4 EPS of -$1.00 missed expectations.
High implied volatility (73.61%) and low IV percentile (5.98), indicating limited options trading interest and potential uncertainty.
No recent trading activity from Congress or influential figures.
In Q4 2025, the company reported a net loss of $93.88M, an EPS of -0.98 (improved YoY by 55.56%), and no revenue growth. Operating expenses remain high at $45.95M, primarily focused on R&D. The company has decreasing cash reserves and increasing debt, raising concerns about financial sustainability.
Analysts remain optimistic, with recent Buy ratings from Canaccord, Stifel, and Morgan Stanley. Price targets have been adjusted to a range of $14-$22, reflecting confidence in the company's clinical trial results and potential FDA approval for COMP360. However, some firms have lowered their targets due to financial concerns and missed Q4 expectations.
